 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Pembrolizumab monotherapy for untreated advanced hepatocellular carcinoma

Clin Cancer Res: Pembrolizumab monotherapy for untreated advanced hepatocellular carcinoma

 Last Update: 2022-05-26
 Source: Internet
 Author: User

Tags

laxogenin results

paroxetine 10 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Liver cancer is one of the most common malignancies worldwide and the leading cause of cancer-related death

Results of cohort 1 of the KEYNOTE-224 trial showed that pembrolizumab was effective and well tolerated in patients with advanced HCC previously treated with sorafenib

Pembrolizumab was effective and well tolerated in patients with advanced HCC previously treated with sorafenib

The KEYNOTE-224 trial is an open-label, multi-country, phase II clinical trial that enrolled 2 cohorts of patients with advanced HCC who had not received prior systemic therapy and were unsuitable or refractory to local therapy, and were treated with pembrolizumab (200 mg/kg/day).

Secondary endpoints included duration of response, disease control rate, time to progression, progression-free survival, overall survival, and safety/tolerability

51 The objective response rate was 16% The objective response rate was 16% The median duration of response was 16 months, and the disease control rate was 57% The median duration of response was 16 months, and the disease control rate was 57%

In conclusion, in patients with advanced HCC who have not received prior systemic therapy, pembrolizumab therapy provided durable antitumor activity, promising overall survival, and a safety profile consistent with previous reports

In patients with advanced HCC who have not received prior systemic therapy, pembrolizumab treatment provides durable antitumor activity, promising overall survival, and a safety profile consistent with previous reports in patients with advanced HCC who have not received prior systemic therapy pembrolizumab therapy provided durable antitumor activity, promising overall survival, and a safety profile consistent with previous reports

Original source:

Gontran Verset, Ivan Borbath, Mark Karwal, et al.

Gontran Verset, Ivan Borbath, Mark Karwal, et al.
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.
Clin Cancer Res 2022; https://doi.
org/10.
1158/ 1078-0432.
CCR-21-3807

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.